39 results
8-K
EX-99.1
CADL
Candel Therapeutics Inc
23 May 24
Regulation FD Disclosure
5:05pm
conducted under a Special Protocol Assessment with the FDA. The FDA has also granted Orphan Drug Designation to CAN-2409 for the treatment of PDAC.
About
8-K
EX-99.1
CADL
Candel Therapeutics Inc
25 Apr 24
Candel Therapeutics Announces Upcoming Presentations
8:30am
phase 3 clinical trial in prostate cancer is being conducted under a Special Protocol Assessment by FDA. The FDA has also granted Orphan Drug Designation
8-K
EX-99.1
jrw6vyjxnhdhlqh
11 Apr 24
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
9:00am
8-K
EX-99.1
tp1ofy3a7 6j9oyjo
4 Apr 24
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
8:30am
8-K
EX-99.1
bjrn6fhv2j4f
12 Dec 23
Candel Therapeutics Receives FDA Fast Track Designation for CAN‑2409 in Pancreatic Cancer
8:30am
8-K
EX-99.1
gfsg7n38tpcqawvm14l
19 May 23
Regulation FD Disclosure
9:15am
8-K
EX-99.1
wnb5 4mf2
6 Dec 22
Regulation FD Disclosure
8:01am
DEF 14A
qwbw8pq7xuof7ig8qzxx
2 Sep 22
Definitive proxy
8:30am